Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
Participants will be assigned to A or B groups with a scale of 1:1 based on a prospectively randomized treatment-sequence assignment, i.e. infuse SCT800 followed by Xyntha (group A), or the alternate sequence (group B). All participants who completed the SCT800HA1 study will enter the efficacy and safety study (Protocol No.: SCT800HA3).
Epistemonikos ID: 7ec7aec2f4816ddef5352147a0f924c6610b4b32
First added on: Jun 14, 2024